Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Clin Med ; 13(17)2024 Aug 25.
Artigo em Inglês | MEDLINE | ID: mdl-39274244

RESUMO

Despite advances in ablative therapies, outcomes remain less favorable for persistent atrial fibrillation often due to presence of non-pulmonary vein triggers and abnormal atrial substrates. This review highlights advances in ablation technologies and notable scientific literature on clinical outcomes associated with pursuing adjunctive ablation targets and substrate modification during persistent atrial fibrillation ablation, while also highlighting notable future directions.

2.
J Cardiovasc Dev Dis ; 10(7)2023 Jun 27.
Artigo em Inglês | MEDLINE | ID: mdl-37504529

RESUMO

Atrial fibrillation is a diverse clinical entity, with persistent atrial fibrillation (PeAF) being particularly challenging to manage. Through this paper, we discuss notable developments in our understanding of ablative strategies for managing PeAF, with a special focus on posterior wall isolation (PWI).

3.
Cardiooncology ; 6: 22, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33062307

RESUMO

This is a case of a middle-aged woman with underlying cardiac conduction system with episodes of AV Wenckebach, who subsequently developed significant AV conduction system abnormalities after receiving one standard dose of Rituximab infusion for diffuse large B-cell lymphoma. Rituximab, being a monoclonal antibody against CD-20 antigen, is effective in treatment of B-cell lymphoma but may also cause bradyarrythmias likely due to the calcium ion channel property of CD-20 antigen.

5.
Expert Rev Cardiovasc Ther ; 6(2): 249-60, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18248278

RESUMO

Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a cardiac disease characterized by fibrofatty replacement of the cardiac myocytes. Patients with ARVD/C frequently present with ventricular tachycardia and many are thought to have sudden cardiac death as the initial manifestation of the disease. Over the past decade, our understanding of the disease has increased dramatically along with delineation of the genetic basis of ARVD/C and characteristic features on diagnostic imaging. The management of patients with ARVD/C remains a challenge, especially in the light of incomplete genotype-phenotype characterization, and poor predictors of sudden cardiac death. In this article, we review the pathologic and genetic basis of ARVD/C, focusing on the diagnostic features and therapeutic challenges emerging with our enhanced knowledge of this rare disease.


Assuntos
Displasia Arritmogênica Ventricular Direita/diagnóstico , Displasia Arritmogênica Ventricular Direita/terapia , Cardiomiopatias/diagnóstico , Cardiomiopatias/terapia , Antiarrítmicos/uso terapêutico , Displasia Arritmogênica Ventricular Direita/genética , Displasia Arritmogênica Ventricular Direita/fisiopatologia , Procedimentos Cirúrgicos Cardíacos , Cardiomiopatias/genética , Cardiomiopatias/fisiopatologia , Ablação por Cateter , Cineangiografia , Desfibriladores Implantáveis , Ecocardiografia , Eletrocardiografia , Humanos , Imageamento por Ressonância Magnética , Miocárdio/patologia , Tomografia Computadorizada por Raios X
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa